查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827440

肝癌药物市场按治疗类型、癌症类型、给药途径、药物类别、最终用户和分销管道划分－2025-2032 年全球预测

Liver Cancer Drugs Market by Therapy Type, Cancer Type, Administration Route, Drug Class, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，肝癌治疗市场规模将成长至 29.0638 亿美元，复合年增长率为 14.44%。

主要市场统计数据
基准年2024年 9.876亿美元
预计2025年 1,127,840,000美元
预测年份：2032年 2,906,380,000美元
复合年增长率（%） 14.44%

免疫肿瘤学整合、精准医疗和复杂的递送挑战推动肝癌治疗模式的不断发展

肝癌治疗正处于曲折点，其特征是科学进步日新月异、临床模式不断转变以及商业性动态不断演变。近年来，免疫肿瘤学方法与成熟的标靶治疗和细胞毒性方案的稳步整合，催生了结合全身和局部干预的多学科治疗途径。因此，临床医生、付款方和製造商正在重新评估治疗流程，以优化治疗效果，同时克服药物可近性障碍和复杂的报销环境。

从传统的单药治疗模式转向组合方案的转变，为临床开发、监管核准和市场部署带来了新的机会，也带来了新的复杂性。透过分子分析进行患者分层，以及真实世界证据日益增长的重要性，正在重塑临床试验设计和核准后证据的生成。因此，策略性相关人员必须在创新与实际考量（例如供应链弹性、定价策略和相关人员教育）之间取得平衡，以确保治疗进展能够转化为患者的福祉。

最终，现代医疗格局需要一个奖励观点，将不断发展的科学、多方相关人员以及不同环境下医疗服务的现实纳入考量。本引言为深入探讨颠覆性变革、政策影响、细分市场细微差别、地理差异、竞争模式以及本执行摘要摘要之后的行动建议奠定了基础。

免疫肿瘤学的突破、精准诊断和新型给药模式如何重新定义肝癌的治疗和护理

由于免疫疗法、标靶小分子药物和联合治疗的突破，肝癌治疗格局正在发生重大转变。查核点抑制剂和抗血管新生药物的组合改变了一线治疗途径，而针对特定分子异常的标靶抑制剂则为此前服务不足的亚群拓展了治疗选择。同时，诊断准确性的提高（包括更广泛的分子谱分析）使患者能够更精确地匹配治疗方法，从而加速了个人化治疗方案的进程。

由于部分联合治疗已被证明在生存和耐受性方面均具有临床益处，支付方和医疗机构系统正在重新调整治疗路径，以纳入这些创新。这种调整正在推动肿瘤中心、诊断实验室和专科药房之间建立新的合作，以提供一体化治疗。此外，口服标靶治疗和皮下注射剂型的兴起正在改变给药模式，并促成门诊和居家护理模式，从而减轻住院负担，并提高患者便利性。

同时，监管框架也在不断发展，以适应适应性试验设计和加速核准途径，鼓励申办方追求新的终点和替代指标。因此，治疗轨迹不仅由科学进步决定，还受到医疗保健服务、监管互动和商业性执行的系统性转变的影响，这些转变共同重新定义了肝臟恶性肿瘤的最佳治疗方案。

评估2025年关税变化如何增加供应链脆弱性、影响定价结构并加速本地生产策略

2025年关税的实施和贸易政策的变化凸显了全球医药供应链和采购惯例中现有的脆弱性，对肝癌治疗生态系统产生了累积影响。活性药物原料药、辅料和成品的进口关税提高，增加了製造商和经销商的到岸成本，促使他们重新评估筹资策略，并可能调整其商业定价模式。因此，医疗保健提供者和付款人可能面临影响处方决策和患者可及性计划的定价压力。

此外，关税可能会加速製造业在地化进程，增强区域供应弹性，鼓励对地理分散的生产能力和策略性储备进行投资。虽然回流和近岸外包可以缓解未来的中断风险​​，但也会带来短期资本支出，以及与建立合规製造地相关的监管复杂性。因此，无论是市场参与企业或现有企业，在规划製造地时都必须权衡成本、敏捷性和合规性之间的优点和缺点。

此外，贸易政策波动可能会影响临床试验的供应计划以及患者筛选所需的专用检测试剂的可用性，从而可能影响下游的入组和试验时间表。对于跨多个司法管辖区运营的相关人员而言，关税增加了一层战略不确定性，凸显了灵活的合约、严格的供应商资格以及与付款方积极沟通的重要性，以便在成本结构不断变化的情况下维持患者的可及性。

全面的细分洞察揭示了治疗方式、癌症亚型、给药途径和通路如何影响治疗的采用

市场区隔分析透过从治疗类型、癌症亚型、给药途径、药物类别、最终用户和通路方面构建市场框架，为理解肝癌的治疗需求和治疗方案的实施提供了细緻入微的视角。按治疗类型（例如化疗、免疫疗法、放射线治疗和标靶治疗）对治疗进行分类，使我们能够观察到不同治疗方案的临床发展轨迹和资源影响。同样，按癌症类型（例如胆管癌、肝母细胞瘤和肝细胞癌）进行细分，可以揭示未满足需求的差异、受年龄和生物学影响的治疗选择以及利基创新机会。

按给药途径（包括静脉注射、口服和皮下注射）进行细分，揭示了给药方式如何影响患者依从性、门诊病人利用率和治疗经济性。依药物类别，我们区分了细胞毒性药物、单株抗体和蛋白酪氨酸激酶抑制剂，每种药物都有其独特的安全性、监测和开发特性，决定了其临床应用。将最终用户细分为居家医疗、医院和专科诊所，揭示了治疗的运作途径以及相应的患者教育和监测要求。

最后，一项涵盖医院、线上和零售药局的分销管道分析，揭示了获取途径、履约的复杂性以及数位化和专业配药模式的演变。这些细分观点可以帮助相关人员确定有针对性的商业化策略，优先考虑亚群体的证据生成，并设计符合临床实践和患者偏好的交付模式。

影响美洲、欧洲、中东和非洲以及亚太地区治疗采用和交付的差异化因素和可近性推动因素

区域动态对治疗方法的可近性、监管途径和商业策略有重大影响，美洲、欧洲、中东和非洲以及亚太地区之间存在明显差异。在美洲，先进的肿瘤学基础设施、广泛的临床试验网路以及先进的报销框架使得新型系统性治疗方案能够相对快速地被采用。专科医疗中心的地理集中也有利于对复杂病例进行加护治疗，但在贫困地区，治疗可近性仍有差异。

欧洲、中东和非洲地区管理体制和医疗资金筹措模式的差异，导致医疗服务的可近性和采用率参差不齐。高所得的欧洲市场通常能够更快地采纳指南建议和更广泛的报销途径，而资源受限的地区则必须在高成本创新与相互竞争的医疗保健优先事项之间取得平衡，这导致人们对分级定价和可及性计划的兴趣日益浓厚。中东和非洲部分地区在基础设施和诊断能力方面面临独特的挑战，因此需要采取独特的采用方法。

亚太地区呈现出多元化的频谱，既有由大型公共卫生系统和积极的国内製造业推动的先进市场，也有诊断能力和分销物流仍在不断扩展的新兴市场。监管现代化努力和本地临床开发伙伴关係是该地区的突出趋势，既支持全球临床项目，也支持地方治疗创新。在整个地区，跨境合作、技术支援的医疗模式和自适应报销机制正在成为扩大病患可近性的重要槓桿。

策略企业模式展示了研发联盟、投资组合多样化和现实世界证据策略如何塑造竞争定位

肝癌治疗领域的关键企业行动体现了一系列策略性研发投资、合作活动和生命週期管理，旨在实现长期成长并维持临床相关性。製药和生技公司越来越重视利用互补作用机制的组合方案，同时也投资伴随诊断，以改善患者选择并向付款人展示价值。大型跨国公司与专业生技公司之间的策略联盟十分常见，有助于加快新药上市速度并共用开发风险。

药物研发管线多元化是核心主题，各公司在小分子激酶抑制剂和细胞毒性药物计画与生物製药、抗体药物复合体和免疫调节平台之间寻求平衡。各公司也专注于开发支持门诊治疗的剂型和给药途径，例如口服和皮下给药，以应对不断变化的医疗服务提供者的偏好。从商业性角度来看，各公司正在扩展患者支援服务和基于价值的安排，以减少药物取得障碍并加强与付款人的关係。

併购和选择性授权交易仍然是加速获取有前景的资产和增强治疗组合的重要槓桿。同时，企业越来越注重真实世界证据的生成和上市后监测，以优化定位、管理安全性并为迭代核准提交提供资讯。总而言之，这些企业策略体现了科学抱负与商业性纪律的务实融合。

为产业领导者提供切实可行的策略指令，以增强供应弹性、精准诊断和以价值为中心的商业化方法

行业领导者必须采取一系列切实可行的措施，以应对快速发展的肝癌治疗格局，并确保患者永续获得药物并实现商业性可行性。首先，他们应优先考虑供应链多元化和策略供应商资格认证，以减少对单一供应商的依赖，并最大限度地降低贸易政策波动和原材料限製造成的中断风险​​。投资区域製造能力和灵活的生产平台可以提高韧性，并加快关键治疗方法的上市时间。

其次，相关人员应投资强大的分子诊断能力和伴随诊断伙伴关係，以实现精准的病患选择、改善临床结果并加强报销案例。第三，付款方和提供者应合作推行基于价值的合约和基于结果的定价模式，使付款与实际绩效保持一致，从而减轻定价压力并促进医疗可及性。第四，整合数位医疗工具、远端医疗和远端监控的跨部门合作可以扩大服务覆盖面，涵盖服务不足的人群，并支持患者坚持口服或皮下注射治疗方案。

最后，公司应从开发早期阶段就优先考虑与监管机构和付款方进行透明的沟通，以协调证据要求，并切实设计核准后的证据生成计划。透过将以临床为中心的商业化策略与营运韧性相结合，产业领导者可以加速创新治疗方法的采用，同时确保长期永续性。

我们的方法框架将专家的初步研究与严格的二次研究相结合，以检验临床、监管和商业见解

这项综合性研究采用混合方法，将专家的主要意见与全面的二次分析相结合，旨在为肝癌药物提供稳健且站得住脚的观点。主要研究包括与临床意见领袖、肿瘤药剂师、付款人代表和高级商业高管进行结构化访谈和咨询，以了解现实世界的实践模式、报销动态和战略重点。这些专家见解被用于整理趋势并检验从文献分析中得出的主题。

二次研究包括系统性地查阅同行评审文献、监管指南文件、临床试验註册中心和公司资讯披露，以绘製治疗方法进展、试验结果和证据轨迹。整合来自公共卫生组织和专业协会指南的讯息，以了解护理标准和诊断采用模式的变化。透过交叉引用多个独立资讯来源和反覆专家检验，确保数据品质。

本调查方法的局限性包括临床证据和政策环境的演变，这些因素在研究期结束后可能会发生变化。为了缓解这一局限性，该方法强调数据来源的透明记录，并鼓励持续监测监管决策和关键临床结果。该调查方法兼顾深度和广度，以支持战略决策，同时也认识到随着领域发展需要定期更新。

最终的综合报告强调，需要协调科学创新、营运弹性和以付款人为中心的证据，以将治疗方法进展转化为患者利益

总而言之，肝癌治疗领域正在再形成：免疫肿瘤学和标靶药物的科学创新、不断发展的医疗服务提供和管理方法，以及贸易政策和区域可及性差异等外部压力。这些力量正在创造改善患者预后的新机会，同时也带来了营运和报销方面的复杂性，产业、医疗服务提供者和付款人必须共同应对。最终的结果是，一个更具活力、以病人为中心的环境将更有利于精准、灵活和实证的商业化。

展望未来，重视诊断整合、供应链韧性和以支付者为导向的价值展示的相关人员将更有能力将创新转化为持续的临床和商业性成功。此外，适应性监管参与和策略伙伴关係（包括临床和商业）仍将是加速患者可及性的关键槓桿。最终，能否将科学前景与实际应用结合，将决定治疗方法为肝癌患者族群带来持续的益处。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 免疫查核点抑制剂联合治疗在晚期肝细胞癌治疗的应用日益增多
  • 基于基因分析的生物标记主导的精准医疗在肝癌治疗中的整合
  • 扩大肝动脉栓塞合併全身性治疗治疗中期肝细胞癌
  • 针对肝癌抗原的下一代 CAR-T 和 T 细胞受体疗法的开发
  • 真实世界证据和数位健康监测在肝细胞癌治疗中的重要性日益增加
  • 肝癌治疗中新型多激酶抑制剂的市场进入挑战与定价策略

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章肝癌药物市场（依治疗类型）

  • 化疗
  • 免疫疗法
  • 放射治疗
  • 标靶治疗

第九章肝癌治疗药物市场（按癌症类型）

  • 胆管癌
  • 肝母细胞瘤
  • 肝细胞癌（HCC）

第10章肝癌治疗药物市场依给药途径

  • 静脉
  • 口服
  • 皮下

第11章肝癌药物市场（依药物类别）

  • 细胞毒性药物
  • 单株抗体
  • 蛋白酪氨酸激酶抑制剂（TKI）

第12章肝癌药物市场（依最终用户）

  • 居家护理
  • 医院
  • 专科诊所

第十三章肝癌药物市场（依通路）

  • 医院药房
  • 网路药局
  • 零售药局

第十四章肝癌药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章肝癌药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章肝癌药物市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Bayer AG
    • Eisai Co., Ltd.
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd
    • Ipsen SA
    • AstraZeneca plc
    • Exelixis, Inc.
Product Code: MRR-434CCDA05287

The Liver Cancer Drugs Market is projected to grow by USD 2,906.38 million at a CAGR of 14.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 987.60 million
Estimated Year [2025] USD 1,127.84 million
Forecast Year [2032] USD 2,906.38 million
CAGR (%) 14.44%

An evolving therapeutic paradigm in liver oncology driven by immuno-oncology integration, precision medicine, and complex delivery challenges

Liver cancer therapeutics are at an inflection point, characterized by rapid scientific advances, shifting clinical paradigms, and evolving commercial dynamics. Recent years have seen the steady integration of immuno-oncology approaches alongside established targeted therapies and cytotoxic regimens, prompting multidisciplinary care pathways that blend systemic treatments with locoregional interventions. As a result, clinicians, payers, and manufacturers are re-evaluating treatment algorithms to optimize outcomes while navigating access barriers and complex reimbursement environments.

Transitioning from historical monotherapy models to combination regimens has created new opportunities and new complexities for clinical development, regulatory approval, and market deployment. Patient stratification through molecular profiling and the growing importance of real-world evidence are reshaping trial design and post-approval evidence generation. Consequently, strategic stakeholders must balance innovation with pragmatic considerations such as supply chain resilience, pricing strategies, and stakeholder education to ensure that therapeutic advances translate into measurable patient benefit.

Ultimately, the modern landscape demands an integrated perspective that accounts for evolving science, multi-stakeholder incentives, and the operational realities of delivering care across diverse settings. This introduction sets the stage for a deeper exploration of the disruptive shifts, policy influences, segmentation nuances, geographic differentials, competitive maneuvers, and recommended actions that follow in this executive summary.

How immuno-oncology breakthroughs, precision diagnostics, and novel administration models are collectively redefining liver cancer treatment and care delivery

The liver cancer treatment landscape has undergone transformative shifts driven by breakthroughs in immunotherapy, targeted small molecules, and combination strategies. Checkpoint inhibition paired with antiangiogenic agents has altered frontline care pathways, while targeted inhibitors for specific molecular aberrations have expanded options for previously underserved subpopulations. Concurrently, improvements in diagnostic precision, including more widespread molecular profiling, have made it possible to match patients to therapies with greater accuracy, accelerating the move toward personalized regimens.

As clinical benefits have been demonstrated in both survival and tolerability for select combinations, payer and provider systems are recalibrating care pathways to incorporate these innovations. This recalibration has prompted new collaborations between oncology centers, diagnostic laboratories, and specialty pharmacies to deliver integrated care. Moreover, the growth of oral targeted therapies and subcutaneous formulations is changing administration dynamics, enabling more outpatient and home-based care models that reduce hospital burden and improve patient convenience.

In parallel, regulatory frameworks are evolving to accommodate adaptive trial designs and accelerated approval pathways, which has encouraged sponsors to pursue novel endpoints and surrogate markers. As a result, the therapeutic trajectory is defined not only by scientific advances but by systemic shifts in care delivery, regulatory interaction, and commercial execution that together are redefining what constitutes best-in-class treatment for liver malignancies.

Assessment of how 2025 tariff shifts are compounding supply chain fragility, influencing pricing structures, and accelerating localized manufacturing strategies

The introduction of tariffs and trade policy shifts in 2025 has had a cumulative impact on the liver cancer therapeutic ecosystem by accentuating pre-existing vulnerabilities in global pharmaceutical supply chains and procurement practices. Increased import duties on active pharmaceutical ingredients, excipients, and finished formulations can raise landed costs for manufacturers and distributors, prompting reassessment of sourcing strategies and potential adjustments to commercial pricing models. In turn, healthcare providers and payers may face pricing pressures that influence formulary decisions and patient access programs.

Moreover, tariffs can accelerate efforts to regionalize manufacturing and strengthen local supply resilience, prompting investment in geographically diversified production capacity and strategic stockpiling. While reshoring and nearshoring efforts can mitigate future disruption risk, they also introduce short-term capital expenditures and regulatory complexities associated with establishing compliant manufacturing sites. Consequently, market entrants and incumbents must weigh the trade-offs between cost, agility, and compliance in planning their manufacturing footprints.

Furthermore, trade policy volatility may affect the cadence of clinical trial supplies and the availability of specialized assays required for patient selection, with potential downstream impacts on enrollment and study timelines. For stakeholders operating across multiple jurisdictions, tariffs add a layer of strategic uncertainty that underscores the importance of flexible contracting, robust supplier qualification, and proactive engagement with payers to preserve patient access amidst shifting cost structures.

Comprehensive segmentation insights revealing how therapy modalities, cancer subtypes, administration routes, and distribution pathways shape treatment adoption

Segmentation analyses provide a nuanced lens to understand therapeutic demand and delivery in liver cancer by framing the market across therapy type, cancer subtype, administration route, drug class, end user, and distribution channel. When treatments are categorized by therapy type such as chemotherapy, immunotherapy, radiation therapy, and targeted therapy, one can observe distinct clinical trajectories and resource implications across lines of care. Similarly, segmenting by cancer type-covering cholangiocarcinoma, hepatoblastoma, and hepatocellular carcinoma-illuminates differential unmet needs, age- and biology-driven treatment choices, and opportunities for niche innovation.

Administration route segmentation, which includes intravenous, oral, and subcutaneous options, reveals how delivery modality affects patient adherence, outpatient utilization, and the economics of care. Examination by drug class differentiates cytotoxic agents from monoclonal antibodies and tyrosine kinase inhibitors, each bringing a unique safety, monitoring, and development profile that shapes clinical adoption. End user segmentation across home care, hospitals, and specialty clinics highlights the operational pathways through which therapies are delivered and the corresponding requirements for patient education and monitoring.

Finally, distribution channel analysis, spanning hospital pharmacy, online pharmacy, and retail pharmacy, sheds light on access pathways, fulfillment complexity, and the evolving role of digital and specialty dispensing models. Taken together, these segmentation perspectives enable stakeholders to identify targeted commercialization strategies, prioritize evidence generation in subpopulations, and design delivery models that align with clinical practice and patient preferences.

Regional differentiators and access enablers across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence therapeutic adoption and delivery

Regional dynamics exert a strong influence on therapy availability, regulatory pathways, and commercial strategies, with clear distinctions across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, advanced oncology infrastructures, broad clinical trial networks, and progressive reimbursement frameworks have enabled relatively rapid adoption of novel systemic regimens, while payer scrutiny and cost-effectiveness evaluations increasingly shape lifecycle management of therapies. Geographic concentration of specialty centers also facilitates centralized care for complex cases, but disparities in access persist in under-resourced areas.

Within Europe, Middle East & Africa, heterogeneous regulatory regimes and variable healthcare financing models produce a patchwork of access and uptake. High-income European markets often see quicker alignment with guideline recommendations and broader reimbursement pathways, whereas regions with constrained resources must balance high-cost innovations against competing health priorities, driving interest in tiered pricing and access programs. The Middle East and parts of Africa face distinct infrastructure and diagnostic capacity challenges that require tailored implementation approaches.

Asia-Pacific exhibits a spectrum from advanced market adoption, driven by large public health systems and active domestic manufacturing, to emerging markets where diagnostic capacity and distribution logistics are still expanding. Regulatory modernization efforts and local clinical development partnerships are notable trends in the region, supporting both global clinical programs and regionally specific therapeutic innovations. Across all regions, cross-border collaboration, technology-enabled care models, and adaptive reimbursement mechanisms are emerging as critical enablers of broader patient access.

Strategic corporate patterns showing how R&D alliances, portfolio diversification, and real-world evidence strategies are shaping competitive positioning

Key corporate behaviors in the liver cancer therapeutics arena reveal a mix of strategic R&D investment, partnering activity, and lifecycle management aimed at sustaining long-term growth and clinical relevance. Pharmaceutical and biotechnology companies are increasingly prioritizing combination regimens that leverage complementary mechanisms of action, while also investing in companion diagnostics to improve patient selection and demonstrate value to payers. Strategic alliances between large multinationals and specialist biotech firms are commonplace, enabling speed-to-market for novel agents and the sharing of development risk.

Pipeline diversification is a central theme, with firms balancing small-molecule kinase inhibitors and cytotoxic programs alongside biologics, antibody-drug conjugates, and immune-modulating platforms. Companies are also focused on developing formulations and administration routes that support outpatient care, including oral and subcutaneous options that align with shifting provider preferences. From a commercial perspective, leaders are expanding patient support services and value-based arrangements to mitigate access hurdles and strengthen payer relationships.

Mergers and acquisitions, as well as selective licensing deals, remain important tools for accelerating access to promising assets and augmenting therapeutic portfolios. In parallel, firms are placing greater emphasis on real-world evidence generation and post-marketing surveillance to refine positioning, manage safety considerations, and inform iterative regulatory submissions. Collectively, these corporate strategies underscore a pragmatic convergence of scientific ambition and commercial discipline.

Actionable strategic directives for industry leaders to strengthen supply resilience, precision diagnostics, and value-focused commercialization approaches

Industry leaders must adopt a set of pragmatic, actionable measures to navigate the rapidly evolving liver cancer therapeutics landscape and to ensure sustainable patient access and commercial viability. First, supply chain diversification and strategic supplier qualification should be prioritized to reduce dependency on single-source suppliers and to minimize the disruption risk posed by trade policy fluctuations or raw material constraints. Investments in regional manufacturing capacity and flexible production platforms can both improve resilience and shorten time-to-market for critical therapies.

Second, stakeholders should invest in robust molecular diagnostic capabilities and companion diagnostic partnerships to enable precise patient selection, which enhances clinical outcomes and strengthens reimbursement cases. Third, value-based contracting and outcomes-based pricing models should be pursued in collaboration with payers and providers to align payment with real-world performance, thereby mitigating pricing pressure while facilitating access. Fourth, cross-sector collaborations that integrate digital health tools, telemedicine, and remote monitoring can expand reach to underserved populations and support adherence to oral or subcutaneous regimens.

Finally, companies should emphasize transparent engagement with regulators and payers early in development to align on evidentiary requirements and to design pragmatic post-approval evidence-generation plans. By combining operational resilience with clinically focused commercialization strategies, industry leaders can accelerate uptake of innovative therapies while safeguarding long-term sustainability.

Methodological framework combining expert primary research with rigorous secondary synthesis to validate clinical, regulatory, and commercial insights

This research synthesis is grounded in a mixed-methods approach that triangulates primary expert input with comprehensive secondary analysis to provide a robust, defensible perspective on liver cancer therapeutics. Primary research consisted of structured interviews and consultations with clinical thought leaders, oncology pharmacists, payer representatives, and senior commercial executives to capture real-world practice patterns, reimbursement dynamics, and strategic priorities. These expert insights were used to contextualize trends and validate themes emerging from documentary analysis.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to map therapeutic advances, trial outcomes, and evidence trajectories. Information from public health agencies and specialty society guidelines was synthesized to understand standard-of-care shifts and diagnostic adoption patterns. Data quality was ensured through cross-referencing of multiple independent sources and iterative validation with subject matter experts.

Limitations of the methodology include the evolving nature of clinical evidence and policy environments, which may change subsequent to the research window. To mitigate this, the approach emphasizes transparent documentation of data provenance and encourages ongoing monitoring of regulatory decisions and major clinical readouts. The methodology balances depth and breadth to support strategic decision-making while acknowledging the need for periodic updates as the field advances.

Final synthesis emphasizing the need to align scientific innovation, operational resilience, and payer-focused evidence to translate therapeutic advances into patient benefit

In conclusion, liver cancer therapeutics are being reshaped by convergent forces: scientific innovation in immuno-oncology and targeted agents, evolving care delivery and administration modalities, and external pressures such as trade policy and regional access disparities. These forces are producing new opportunities for improved patient outcomes while also introducing operational and reimbursement complexities that require coordinated responses from industry, providers, and payers. The net effect is a more dynamic, patient-centric landscape that rewards precision, flexibility, and evidence-driven commercialization.

Moving forward, stakeholders that prioritize diagnostic integration, supply chain resilience, and payer-aligned value demonstration will be better positioned to translate innovation into durable clinical and commercial success. Moreover, adaptive regulatory engagement and strategic partnerships-both clinical and commercial-will remain critical levers for accelerating patient access. Ultimately, the ability to harmonize scientific promise with pragmatic implementation will determine which therapies achieve sustained impact for the diverse populations affected by liver malignancies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of immune checkpoint inhibitor combinations for advanced hepatocellular carcinoma treatment
  • 5.2. Integration of biomarker-driven precision therapies based on genetic profiling in liver cancer management
  • 5.3. Expansion of transarterial radioembolization coupled with systemic therapies in intermediate stage HCC
  • 5.4. Development of next generation CAR T and T cell receptor therapies targeting liver cancer antigens
  • 5.5. Growing emphasis on real-world evidence and digital health monitoring in hepatocellular carcinoma care
  • 5.6. Market access challenges and pricing strategies for novel multi kinase inhibitors in liver cancer therapy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Cancer Drugs Market, by Therapy Type

  • 8.1. Chemotherapy
  • 8.2. Immunotherapy
  • 8.3. Radiation Therapy
  • 8.4. Targeted Therapy

9. Liver Cancer Drugs Market, by Cancer Type

  • 9.1. Cholangiocarcinoma
  • 9.2. Hepatoblastoma
  • 9.3. Hepatocellular Carcinoma (HCC)

10. Liver Cancer Drugs Market, by Administration Route

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Liver Cancer Drugs Market, by Drug Class

  • 11.1. Cytotoxic Agents
  • 11.2. Monoclonal Antibodies
  • 11.3. Tyrosine Kinase Inhibitors (TKIs)

12. Liver Cancer Drugs Market, by End User

  • 12.1. Home Care
  • 12.2. Hospital
  • 12.3. Specialty Clinic

13. Liver Cancer Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Liver Cancer Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Liver Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Liver Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Bayer AG
    • 17.3.2. Eisai Co., Ltd.
    • 17.3.3. Bristol-Myers Squibb Company
    • 17.3.4. Merck & Co., Inc.
    • 17.3.5. F. Hoffmann-La Roche Ltd
    • 17.3.6. Ipsen S.A.
    • 17.3.7. AstraZeneca plc
    • 17.3.8. Exelixis, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LIVER CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA (HCC), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY CYTOTOXIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. GCC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GCC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GCC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. GCC LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. GCC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. GCC LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. GCC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 268. GCC LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 269. GCC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. GCC LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. GCC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. GCC LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. GCC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. GCC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. G7 LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. G7 LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. G7 LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. G7 LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. G7 LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. G7 LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. G7 LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 310. G7 LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 311. G7 LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 312. G7 LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 313. G7 LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. G7 LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. G7 LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. G7 LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. NATO LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. NATO LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. NATO LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. NATO LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. NATO LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. NATO LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. NATO LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 324. NATO LIVER CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 325. NATO LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 326. NATO LIVER CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 327. NATO LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 328. NATO LIVER CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 329. NATO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. NATO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED STATES LIVER CANCER DRUGS MARKET S